SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7103-7112

  Martinez, Ana ^a,d   Alonso, Mercedes ^a,d   Castro, Ana ^a,d   Dorronsoro, Isabel ^a,d   Gelpí, J Luis ^c   Luque, F Javier ^c   Pérez, Conceptión ^a   Moreno, Francisco J ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b CSIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d NeuroPharma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBONYL DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN B; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYDANTOIN DERIVATIVE; HYMENIALDISINE; INDIRUBIN; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; NITROGEN; PAULLONE DERIVATIVE; PROTEIN KINASE C; RHODANINE; SULFUR; THIADIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG STRUCTURE; ENZYME INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; GLYCOGEN SYNTHASE KINASE 3; HYDANTOINS; MALEIMIDES; MODELS, MOLECULAR; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RHODANINE; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 28544449332     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040895g     Document Type: Article

References (54)

1. Wauwe, J. V.; Haefner, B. Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug New Perspect. 2003, 16, 557-565.
2. Cohen, P.; Goedert, M. GSK-3 inhibitors: Development and therapeutic potential. Nat. Rev. Drug Discovery 2004, 3, 479-487.
3. Kaidanovich, O.; Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opin. Ther. Targets 2002, 6, 555-561.
4. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signalling. Prog. Neurobiol. 2001, 65, 391-426.
5. Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M. S.; Jin, O.; Woodgett, J. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Nature 2000, 406, 86-90.
6. Martinez, A.; Castro, A.; Dorronsoro, I; Alonso, M. Glycogen Synthase Kinase 3 Inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflamation. Med. Res. Chem. 2002, 22, 373-384.
7. Dorronsoro, I.; Castro, A.; Martinez, A. Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs?. Expert Opin. Ther. Pat. 2002, 12, 1527-1536.
8. Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenaldisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.20.
9. Leost, M.; Schultz, C.; Link, A.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-Sbeta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
10. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y. Z.; Mandelkow, E. M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors. J. Biol. Chem. 2001, 276, 251-260.
11. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders: M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-Anilino-4- arylmaleimides: Potent and selective inhibitors of Glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
12. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45, 1292-1299.
13. Ter Haar, E.; Coll, J. T.; Austen, D. A.; Hsiao, H. M.; Swenson, L.; Jain, J. Structure of GSK-3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 2001, 8, 593-596.
14. Dajani, R.; Fraser, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H. Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition. Cell 2001, 705, 721-732.
15. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3 active site using selective and nonselective ATP-mimetic inhibitors. J. Mol. Biol. 2003, 33, 393-407.
16. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormo, M.; Nilsson, Y.; Radesater, A. C.; Jerning, E.; Markgren, P. O.; Borgegard, T.; Nylof, M.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J.; Diaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003, 278, 45937-45945.
17. Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255-1266.
18. Polychronopoulos, P.; Magiatis, P.; Skaltsounis A.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M., Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
19. Alonso, M.; Martínez, A. GSK-3 inhibitors: discoveries and developments. Curr. Med. Chem. 2004, 11, 753-761.
20. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (ComFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 770, 5959-5967.
21. Walker, A. M. A high yielding synthesis of N-alkyl maleimides using a novel modification of the Mitsunobu reaction. J. Org. Chem. 1995, 60, 5352-5355.
22. Zumach, G.; Weiss, W.; Kühle, E. Belgian Pat. 682820. Farbenfabriken Bayer A. G., June 1966.
23. MacLauchlin, C.; May, I. H.; Izydore, R. A. Synthesis and Cytotoxic action of 1-Oxoalkyl and l,2-Dioxoalkyl-l,2,4-triazolidine-3,5-diones in Murine and Human tissue cultured Cells. Arch. Pharm. Pharm. Med. Chem. 1999, 332, 225-232.
24. Hoshitsugu, A.; Matsui, M.; Fujii, A.; Kontani, T.; Koshiyuki, O.; Koizumi, T.; Shiro. M. Asymmetric Diels-Alder Reaction of optically active a-(2-exo-Hydroxy-O-bornyl)-sulfinylmaleimides and its applicattion to optically active 5-functionalized Pyrrolines via Retro-Diels-Alder Reaction. J. Chem. Soc., Perkin. Trans. 1 1994, 25-39.
25. Corrie, J. E. T. Thiol-reactive Fluorescent Probes for Protein Labelling. J. Chem. Soc., Perkin. Trans, 1 1994, 2975-2982.
26. Janda, K. D.; Ashley, J. A.; Jones, T. M.; McLeod, D. A.; Schloeder, D. M.; Weinhous. M. I. Inmobilized Catalytic Antibodies in Aqueous and Organic Solvents. J. Am. Chem. Soc. 1990, 772, 8886-8888.
27. Foye, W. O.; Tovivich, P. N-Glucopyranosyl-5-Aralkylidenerhodanines: Synthesis and Antibacterial and Antiviral Activities. J. Pharm. Sci. 1977, 66, 1607-1611.
28. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Fujiwara, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel Hepatitis C Virus Protease Inhibitors: Thiazolidine Derivatives. Biochem. Biophys. Res. Commun. 1997, 238, 643-647.
29. Mishra, S.; Srivastava, S. K.; Srivastava, S. D. Synthesis of 5-arylidene-2-aryl-3-(phenothiazino/benzo-triazoloacetamidyl)-1, 3-thiazolidine-4-ones as antiinflamatory, anticonvulsant, analgesic and antimicrobial agents. Indian. J. Chem. Sect. B. 1997, 36, 826-830.
30. Peet, N. P. Genomics Research: Where are the drugs? Idrugs 2000, 3, 131-132.
31. Gelpi, J. L., Kalko, S. G., Barril, X., Cirera, J., de la Cruz, X., Luque, F. J., Orozco, M. Classical molecular interaction potentials: improved setup procedure in molecular dynamics simulations of proteins. Proteins 2001, 45, 428-437.
32. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3β active site using selective and nonselectve ATP-mimetic inhibitors. J. Mol. Biol. 2003, 333, 393-407.
33. Paul, N.; Rognan, D. ConsDock: A new program for the consensus analysis of protein-ligand interactions. Proteins 2002, 47, 521-533.
34. Cohen, M. S.; Zhang, C.; Shokat, K. M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005, 308, 1318-1321.
35. Martin-Aparicio, E., Fuertes, A., Perez-Puerto, M. J., Perez, D., Alonso, M., Martinez, A., Medina, M. TDZDs: GSK-3 inhibitors as therapeutic agents for Alzheimer's disease and others tauopathies. Neurobiol. Aging 2004, 25, S596.
36. Girard, M. L.; Dreux, C. Possibilités Réactionnelles et Structurales de dérivés de la Thiazolidine. I.-Addition, Substitution, Hydrolyse. Bull. Soc. Chim. Fr. 1968, 3, 3461-3468.
37. Zumach, G.; Weiss, W.; Kühle, E., British Patent 1,136,737 (June, 1966); Chem. Abstr. 1969, 70, 7795.
38. MacLauchlin, C.; May, I. H.; Izydore, R. A. Synthesis and cytotoxic action of 1-oxoalkyl and 1,2-dioxoalkyl-1,2,4-triazolidine-3,5-diones in murine and human tissue cultured cells. Arch. Pharm. Pharm. Med. Chem. 1999, 332, 225-232.
39. Woodget, J. R. Use of peptide substrates for affinity purification of protein-serine kinases. Anal. Biochem. 1989, 180, 237-241.
40. Parker, G. J.; Law, T. L.; Lenoch, F. J.; Bolger, R. E. Development of High Through-put screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase*/phosphatase assays. J. Biomol. Screen. 2000, 5, 77-88.
41. 2+/calmodulin-dependent protein kinase II by its ATP-binding domain. J. Neurochem. 2001, 76, 1066-1072.
42. Carpenter, G.; King, L.; Cohen, S. Rapid enhancement of protein phosphorylation in A-431 cell membrane preparation by epidermal growth factor. J. Biol. Chem. 1979, 254, 4884-4891.
43. Al-Hasani, H.; Pablack, W.; Klein, H. W. Phosphoryl exchange is involved in the mechanism of the insulin receptor kinase. FEBS Lett. 1994, 349, 17-22.
44. Robbins, D. J.; Zhen, E.; Owaki, H. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 1993, 26, 5097-5106.
45. Williams, D. H.; Wilkinson, S. E.; Purton, T.; Lamont, A.; Flotow, A.; Murray, E. J. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry 1998, 37, 9579-9585.
46. Cheng, H. C.; Nishio, H.; Hatase, O.; Ralph, S.; Wang, J. H. A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of Src-family tyrosine kinases. J. Biol. Chem. 1992, 13, 9248-9256.
47. Gastaiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
48. Dewar, M. J. S., Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 707, 3902-3909.
49. Stewart, J. J. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
50. Gaillard, P., Carrupt, P. A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J. Comput.-Aided Mol. Des. 1994, 8, 83-96.
51. SYBYL Molecular Modelling Package, version 6.6; Tripos St. Louis, MO.
52. Mehler, E. L.; Solmajer, T. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng. 1991, 4, 903-910.
53. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Fergurson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins nucleic acids and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
54. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints from deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97, 10268-10280.